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Ciliary neurotrophic factor (CNTF) is primarily
known for its roles as a lesion factor released by the
ruptured glial cells that prevent neuronal degenera-
tion. However, CNTF has also been shown to cause
weight loss in a variety of rodent models of obesity/
type II diabetes, whereas a modified form also causes
weight loss in humans. CNTF administration can cor-
rect or improve hyperinsulinemia, hyperphagia, and
hyperlipidemia associated with these models of obe-
sity. In order to investigate the effects of CNTF on fat
cells, we examined the expression of CNTF receptor
complex proteins (LIFR, gp130, and CNTFR) during
adipocyte differentiation and the effects of CNTF on
STAT, Akt, and MAPK activation. We also examined
the ability of CNTF to regulate the expression of adi-
pocyte transcription factors and other adipogenic pro-
teins. Our studies clearly demonstrate that the expres-
sion of two of the three CNTF receptor complex
components, CNTFR and LIFR, decreases during adi-
pocyte differentiation. In contrast, gp130 expression is
relatively unaffected by differentiation. In addition,
preadipocytes are more sensitive to CNTF treatment
than adipocytes, as judged by both STAT 3 and Akt
activation. Despite decreased levels of CNTFR ex-
pression in fully differentiated 3T3-L1 adipocytes,
CNTF treatment of these cells resulted in a time-de-
pendent activation of STAT 3. Chronic treatment of
adipocytes resulted in a substantial decrease in fatty-
acid synthase and a notable decline in SREBP-1 levels
but had no effect on the expression of peroxisome pro-
liferator-activated receptor , acrp30, adipocyte-
expressed STAT proteins, or C/EBP. However, CNTF
resulted in a significant increase in IRS-1 expression.
CNTFR receptor expression was substantially in-
duced in the fat pads of four rodent models of obesity/
type II diabetes as compared with lean littermates.
Moreover, we demonstrated that CNTF can activate
STAT 3 in adipose tissue and skeletal muscle in vivo. In
summary, CNTF affects adipocyte gene expression,
and the specific receptor for this cytokine is induced
in rodent models of obesity/type II diabetes.
Ciliary neurotrophic factor (CNTF)1 was originally charac-
terized as a trophic factor that supports the survival of embry-
onic chick ciliary ganglion neurons in vitro (1, 2). However,
subsequent cloning and sequencing of CNTF revealed that it is
unrelated to neurotrophins but is a member of the gp130 cyto-
kine family along with interleukin-6, interleukin-11, LIF,
OSM, leptin and CT-1 (3–5). The actions of CNTF are medi-
ated, in part, by a CNTF-specific receptor (CNTFR) that has
homology to the interleukin-6R (6). Upon translation, the C
terminus of CNTFR is cleaved. Mature CNTFR has no trans-
membrane or cytosolic domains and is found on the outer
surface of the cell membrane where it is attached by a glyco-
sylphosphatidylinositol linkage sensitive to phosphatidylinosi-
tol-phospholipase C treatment (7). Initially, CNTFR was de-
scribed as being distributed predominantly within neural
tissues (7) but has since been reported in skeletal muscle,
adrenal gland, sciatic nerve, skin, kidney, and testes (8).
CNTFR can be cleaved from the cell surface and exist and act
in a soluble form. The soluble CNTFR has been detected in the
serum and the cerebrospinal fluid and has been shown to
initiate signaling in cells not responsive to CNTF alone (6, 9).
Mice lacking CNTF develop normally and appear to have no
visible defects well into adulthood, when they develop minor
loss of motor neurons (10). However, mice lacking CNTFR
tend to have severe motor neuron defects and die perinatally
because they fail to initiate feeding behaviors (11). CNTF sig-
naling is initiated when CNTF binds CNTFR, either in its
soluble or membrane-bound form (12). Once a CNTFCNTFR
complex is formed, two of these heterodimers come together
and recruit a gp130 transducer protein, followed by a subse-
quent recruitment of LIFR protein. The resulting receptor com-
plex is a hexamer of CNTF, CNTFR, gp130, and LIFR in a
2:2:1:1 ratio, respectively (13). Within this complex, CNTF and
CNTFR make direct contacts with all the complex compo-
nents (7, 12). CNTFCNTFR is considered to be a low affinity
binding complex until further bound to gp130 and LIFR (14).
Aside from this hexameric, high affinity binding complex,
CNTF can bind its receptors and can induce signaling in the
absence of CNTFR, solely by binding to a gp130:LIFR dimeric
receptor (15, 16).
Although CNTF was first identified as a trophic factor in the
ciliary ganglion, it was later found to act on other motor neuron
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populations (17). Hence, it was evaluated as a therapeutic tool
in patients suffering from motor neuron diseases (18). Inter-
estingly, during these trials, CNTF administration resulted in
unexpected weight loss (19). Additional studies showed that,
like leptin, CNTF can activate the same signaling molecules
and that CNTFR is co-localized with ObR in the hypothalamic
nuclei involved in the regulation of feeding (20). CNTF can also
cross the blood-brain barrier in a manner similar to leptin (21).
CNTF treatment of leptin-deficient ob/ob mice was found to
reduce adiposity, hyperphagia, and hyperinsulinemia associ-
ated with this genotype. Leptin administration had the same
effect in these animals. However, unlike leptin, CNTF also
corrected obesity-related phenotypes in leptin-resistant, ObR-
deficient, db/db mice and in mice with diet-induced obesity that
are partially resistant to leptin (22). CNTF and its synthetic
analog, Axokine, have also been found to suppress NPY gene
expression (23) and pCREB in the feeding-relevant brain sites
(22). The weight loss caused by CNTF administration is due to
the preferential loss of fat (24). It is believed to occur by reset-
ting the hypothalamic weight set point, such that cessation of
CNTF treatment does not result in overeating and rebound
weight gain (22). Unlike cachectic cytokines, the appetite dim-
inution during CNTF treatment does not appear to be due to
stress, inflammatory responses, nausea, or conditioned taste
aversion but is possibly due to the modification of NPYergic
signaling (22, 25).
In this study, we examined the regulation and activation of
STATs and proteins by CNTF in adipocytes. The objective of
this project was to determine whether CNTF, a cytokine known
to result in weight loss, could have effects on peripheral tissues
such as white adipose tissue. Our results clearly demonstrate
that two of the three CNTF receptors are down-regulated dur-
ing the adipogenesis of 3T3-L1 cells. However, CNTF adminis-
tration results in the activation of STAT 3 in both cultured
3T3-L1 adipocytes and in rodent adipose tissue. Also this study
provides the first evidence that CNTFR is expressed in adi-
pose tissue and that the expression of this receptor is regulated
in four rodent models of obesity/type II diabetes. We also ob-
served that CNTF treatment did not effect the expression of
key adipogenic transcription factors such as PPAR and
C/EBP but did result in a decrease of fatty-acid synthase
(FAS) expression. Also, unlike other cachectic cytokines such as
tumor necrosis factor-, chronic CNTF treatment did not result
in the development of insulin resistance in cultured adipocytes.
Moreover, acute CNTF administration resulted in increased
GLUT4 expression, whereas chronic CNTF treatment resulted
in a substantial increase in IRS-1 expression. Also, acute CNTF
treatment resulted in an increase in insulin-induced IRS-1 and
Akt activation. In summary, the results of this study demon-
strate that both cultured and native adipocytes, as well as
skeletal muscle, are responsive to CNTF and that this cytokine
may act as an insulin-sensitizer in cultured adipocytes. These
studies support our hypothesis that the ability of CNTF to
result in weight loss is not solely mediated by the central
nervous system.
EXPERIMENTAL PROCEDURES
Materials—Dulbecco’s modified Eagle’s media (DMEM) was pur-
chased from Invitrogen. Bovine and fetal bovine serum (FBS) were
obtained from Sigma and Invitrogen, respectively. Rat CNTF was pur-
chased from Calbiochem. The non-phospho-STAT antibodies were
monoclonal IgGs purchased from Transduction Laboratories or poly-
clonal IgGs from Santa Cruz Biotechnology. A highly phospho-specific
polyclonal antibody for STAT 3 (Tyr705) was purchased from BD Bio-
sciences. LIFR and gp130 were rabbit polyclonals from Santa Cruz
Biotechnology. PPAR was a mouse monoclonal from Santa Cruz Bio-
technology. SREBP-1 and ERK1/ERK2 were rabbit polyclonals from
Santa Cruz Biotechnology. Active ERK antibody was a rabbit polyclonal
from Promega. C/EBP was a rabbit polyclonal from Dr. Ormond Mac-
Dougald (Ann Arbor, MI), and GLUT 4 was a rabbit polyclonal from Dr.
Paul Pilch (Boston). CNTFR was a mouse monoclonal purchased from
BD Biosciences. IRS-1 polyclonal was a polyclonal obtained from Up-
state Biotechology, Inc., and the phospho-specific IRS-1 polyclonal was
from BIOSOURCE International. PGNaseF was obtained from New
England Biolabs.
Cell Culture—Murine 3T3-L1 preadipocytes were plated and grown
to 2 days post-confluence in DMEM with 10% bovine serum. Medium
was changed every 48 h. Cells were induced to differentiate by changing
the medium to DMEM containing 10% fetal bovine serum, 0.5 mM
3-isobutyl-1-methylxanthine, 1 M dexamethasone, and 1.7 M insulin.
After 48 h this medium was replaced with DMEM supplemented with
10% FBS, and cells were maintained in this medium until utilized for
experimentation.
Preparation of Whole Cell Extracts—Monolayers of 3T3-L1 preadipo-
cytes or adipocytes were rinsed with phosphate-buffered saline and
then harvested in a non-denaturing buffer containing 150 mM NaCl, 10
mM Tris, pH 7.4, 1 mM EGTA, 1 mM EDTA, 1% Triton X-100, 0.5%
Nonidet P-40, 1 M phenylmethylsulfonyl fluoride, 1 M pepstatin, 50
trypsin inhibitory milliunits of aprotinin, 10 M leupeptin, and 2 mM
sodium vanadate. Samples were extracted for 30 min on ice and cen-
trifuged at 15,000 rpm at 4 °C for 15 min. Supernatants containing
whole cell extracts were analyzed for protein content using a BCA kit
(Pierce) according to the manufacturer’s instructions.
Preparation of Nuclear/Cytosolic Extracts—Cell monolayers were
rinsed with phosphate-buffered saline and then harvested in a nuclear
homogenization buffer (NHB) containing 20 mM Tris, pH 7.4, 10 mM
NaCl, and 3 mM MgCl2. Nonidet P-40 was added to a final concentration
of 0.15%, and cells were homogenized with 16 strokes in a Dounce
homogenizer. The homogenates were centrifuged at 1500 rpm for 5 min.
Supernatants were saved as cytosolic extract, and the nuclear pellets
were resuspended in 0.5 volume of NHB and were centrifuged as before.
The pellet of intact nuclei was resuspended again in 0.5 of the original
volume of NHB and centrifuged again. A small portion of the nuclei was
used for trypan blue staining to examine the integrity of the nuclei. The
majority of the pellet (intact nuclei) was resuspended in an extraction
buffer containing 20 mM HEPES, pH 7.9, 420 mM NaCl, 1.5 mM MgCl2,
0.2 mM EDTA, and 25% glycerol. Nuclei were extracted for 30 min on ice
and then placed at room temperature for 10 min. Two hundred units of
DNase I was added to each sample, and tubes were inverted and
incubated an additional 10 min at room temperature. Finally, the
sample was subjected to centrifugation at 15,000 rpm at 4 °C for 30 min.
Supernatants containing nuclear extracts were analyzed for protein
content.
Gel Electrophoresis and Immunoblotting—Proteins were separated
in 5, 7.5, 10, or 12% polyacrylamide (acrylamide from National Diag-
nostics) gels containing SDS according to Laemmli (26) and transferred
to nitrocellulose (Bio-Rad) in 25 mM Tris, 192 mM glycine, and 20%
methanol. Following transfer, the membrane was blocked in 4% milk
for 1 h at room temperature. Results were visualized with horseradish
peroxidase-conjugated secondary antibodies (Sigma) and enhanced
chemiluminescence (Pierce). Following chemiluminescence, some re-
sults were quantified by scanning film, and densitometry analysis was
performed with associated analytical software (Biomax, Eastman
Kodak Co.).
Determination of 2-Deoxyglucose—The assay of 2-[3H]deoxyglucose
was performed as described previously (27). Prior to the assay, fully
differentiated 3T3-L1 adipocytes were serum-deprived for 4 h. Uptake
measurements were performed in triplicate under conditions where
hexose uptake was linear, and the results were corrected for nonspecific
uptake, and absorption was determined by 2-[3H]deoxyglucose uptake
in the presence of 5 M cytochalasin B (Sigma). Nonspecific uptake and
absorption were always less than 10% of the total uptake.
Animals and Adipose Tissue Isolation—Seven-week-old ob/ and
ob/ob mice were purchased from The Jackson Laboratories. Eight-week-
old fa/ and fa/fa rats were purchased from Harlan. C57Bl/6J mice
were obtained from The Jackson Laboratories at 3–5 weeks of age, and
upon receipt were placed on a high fat/high sucrose diet (Research Diets
12331, Surwit diet) or a low fat/high sucrose diet (Research Diets
12329). In each experiment, at least five animals were used for each
condition. Twelve-week-old transgenic mice expressing agouti under
the control of the -actin promoter were obtained from a colony at the
Pennington Biomedical Research Center. Rodents were euthanized by
cervical dislocation, and adipose tissue was quickly removed, weighed,
and frozen in liquid nitrogen. Frozen fat pads were homogenized in a
buffer containing 150 mM NaCl, 10 mM Tris, pH 7.4, 1 mM EGTA, 1 mM
EDTA, 1% Triton X-100, 0.5% Nonidet P-40, 1 M phenylmethylsulfonyl
fluoride, 1 M pepstatin, 50 trypsin inhibitory milliunits of aprotinin,
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and 10 M leupeptin, and 2 mM sodium vanadate. Homogenates were
centrifuged for 10 min at 5,000 rpm to remove any debris and insoluble
material and then analyzed for protein content. All animal studies were
carried out with protocols that were reviewed and approved by the
institutional animal care and use committee. Adipocytes were isolated
from the epididymal fat pads of male C57Bl/6J mice (35g) by collagen-
ase digestion.
RESULTS
The sensitivity of 3T3-L1 cells to cytokine treatment was
examined by treating undifferentiated preadipocytes and fully
differentiated 3T3-L1 adipocytes with an acute treatment of 0.8
nM CNTF or 0.8 nM LIF. As shown in Fig. 1, immunoblotting of
whole cell extracts demonstrated that both preadipocytes and
adipocytes express STAT 3. Treatment of both preadipocytes
and adipocytes with LIF or CNTF resulted in the rapid activa-
tion of STAT 3, as evident by increased tyrosine phosphoryla-
tion. However, treatment of preadipocytes resulted in a greater
stimulation of STAT 3 activation, relative to adipocytes, de-
spite equivalent expression of STAT 3 protein. In addition,
CNTF and LIF treatment caused a robust activation of Akt in
preadipocytes, whereas the same treatment of adipocytes did
not result in a detectable activation of Akt. The expression of
two CNTF receptor complex proteins, LIFR and gp130, was
also examined. LIFR was expressed at a substantially higher
level in preadipocytes than in adipocytes, whereas the expres-
sion of gp130 protein was not differentially expressed in these
two cell types.
The expression of CNTF receptor complex proteins was also
examined during a time course of adipocyte differentiation. As
shown in Fig. 2, the expression of CNTFR protein decreases
notably after 15 min of induction of differentiation, and this
lower level of expression is maintained for 48 h. However, there
were no detectable levels of CNTFR 72 h after the initiation of
differentiation in whole cell extracts. Yet we did observe the
presence of CNTFR in the media at 72, 96, and 120 h at lower
levels (data not shown). As indicated in Fig. 1, the expression of
LIFR decreased during adipogenesis, and there was a slight
modulation of gp130 expression. The expression of STAT 5A is
known to be induced during adipocyte differentiation and is
shown as a positive control for adipogenesis.
Because the expression of two CNTF receptor complex pro-
teins was reduced during adipogenesis, we wanted to deter-
mine whether these proteins were expressed in adipose tissue
and to compare the expression levels to other tissues. Whole
cell extracts were isolated from the various tissues indicated in
Fig. 3. Western blot analysis revealed lung, stomach, epididy-
mal fat, spleen, heart, brain, testes, and skeletal muscle as
tissues expressing both CNTFR and LIFR. All of these tissues
had comparable receptor expression levels, except for the brain,
which had significantly higher levels of CNTFR expression.
Also the molecular weight of CNTFR in stomach and brain
was greater than in other tissues. In agreement with our ear-
lier observations (Fig. 2), the expression of CNTFR was abun-
dant in preadipocytes and undetectable in 3T3-L1 adipocytes.
We also observed that the expression of CNTFR was up-
regulated in the epididymal fat pad of an obese Zucker rat as
compared with a lean littermate.
To determine whether the altered mobility of CNTFR was
due to glycosylation, tissue extracts were incubated with PN-
GaseF. As shown in Fig. 4, treatment with PNGaseF resulted
in the deglycosylation of CNTFR and LIFR. In particular, the
CNTFR bands of larger molecular weights (brain and stom-
ach) co-migrated with the CNTFR from other tissues follow-
ing digestion, indicating that the size difference between
CNTFR in these tissues was due to different glycosylation
patterns. Also all LIFR bands migrated at the same molecular
weight following PNGaseF treatment.
Although our results demonstrate that fully differentiated
3T3-L1 adipocytes do not express CNTFR, it has been dem-
onstrated previously (15, 16) that CNTF can signal via gp130
and LIFR in the absence of CNTFR. Therefore, we examined
the ability of CNTF to activate STATs in a time-dependent
manner in 3T3-L1 adipocytes. Serum-deprived fully differenti-
ated 3T3-L1 adipocytes were exposed to CNTF and examined
over an 8-h period. Cells were harvested at the times indicated
at the top of Fig. 5 and fractionated into cytosolic and nuclear
extracts. As shown in Fig. 5A, CNTF administration to 3T3-L1
adipocytes resulted in the nuclear translocation of STAT 3.
STAT 3 was present in the nucleus after a 10- or 30-min
treatment with CNTF, and the amount of STAT 3 nuclear
protein was decreased after a 1-h treatment. After 2 h, there
was little STAT 3 present in the nucleus. CNTF treatment did
not result in the activation/nuclear translocation of STAT 1 or
FIG. 1. The effects of acute CNTF or LIF treatment on 3T3-L1
preadipocytes and adipocytes. Whole cell extracts were prepared
from confluent undifferentiated preadipocytes and from fully differen-
tiated 3T3-L1 adipocytes following a 15-min treatment with CNTF (0.8
nM) or LIF (0.8 nM). Whole cell extracts were prepared, and 75 g of
each extract was separated by SDS-PAGE, transferred to nitrocellulose,
and subjected to Western blot analysis. The detection system was
horseradish peroxidase-conjugated secondary antibodies and enhanced
chemiluminescence. This is a representative experiment independently
performed three times.
FIG. 2. The expression of CNTF receptor complex proteins
during adipocyte differentiation. Whole cell extracts were prepared
from 3T3-L1 cells at various times following the induction of differen-
tiation. Cells were induced to differentiate at 2 days post-confluence
with the addition of a differentiation mixture containing 10% FBS, 0.5
mM 3-isobutyl-1-methylxanthine, 1.0 M dexamethasone, and 1.7 M
insulin. After 48 h this medium was replaced with DMEM supple-
mented with 10% FBS, and cells were maintained in this medium until
utilized for experimentation. One hundred g of each extract was sep-
arated by SDS-PAGE, transferred to nitrocellulose, and subjected to
Western blot analysis. Samples were processed, and results were visu-
alized as described in Fig. 1 legend. This is a representative experiment
independently performed three times.
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STAT 5B, indicating the specificity of the response. Also CNTF
did not effect the distribution of STAT 5A. Unlike other adipo-
cyte-expressed STATs, some STAT 5A is always present in the
adipocyte nucleus (28).
The dose-dependent effects of CNTF on 3T3-L1 adipocytes
were also examined by treating adipocytes for 10 min with
varying concentrations of CNTF. As shown in Fig. 5B, CNTF
had no effect on STATs 1 or 5A but resulted in the tyrosine
phosphorylation and nuclear translocation of STAT 3. In addi-
tion, CNTF treatment resulted in a dose-dependent activation
of MAPK (ERKs 1 and 2). To assess the dose effects of CNTF on
STAT 3 activation, we compared STAT 3 activation in preadi-
pocytes and adipocytes. As shown in Fig. 5C, CNTF results in
a dose-dependent effect on STAT 3 activation in preadipocytes
but not in adipocytes.
To characterize further the effects of CNTF, we treated fully
differentiated 3T3-L1 adipocytes for a 12-h period, and we
isolated whole cell extracts at the times indicated at the top of
Fig. 6. As indicated previously, acute CNTF treatment resulted
in a time-dependent activation of STAT 3 and MAPK but was
unable to activate Akt. A positive control for Akt activation (10
min of treatment of 3T3-L1 adipocytes with 50 nM insulin) is
shown in the bottom panel of Fig. 6. Acute CNTF treatment did
not affect the expression levels of STATs 1, 3, or 5A. There were
also no observable differences in the expression of SREBP-1
protein, as indicated by the levels of the cleaved 67-kDa form of
the protein.
Next, we examined the effects of chronic CNTF administra-
tion on the expression of adipocyte transcription factors and
other adipocyte proteins. Fully differentiated 3T3-L1 adipo-
cytes were exposed to CNTF over a 96-h period. A fresh bolus of
CNTF was added to the cells every 24 h. Whole cell extracts
were isolated at the times indicated at the top of Fig. 7 and
subjected to Western blot analysis. Chronic administration of
CNTF did not alter the expression of adipocyte expressed
FIG. 3. Tissue distribution of CNTF receptor complex compo-
nents in rodents. Tissue extracts were prepared from 8-week-old
Sprague-Dawley rats. Seventy-five g of each extract was separated by
SDS-PAGE, transferred to nitrocellulose, and subjected to Western blot
analysis. Samples were processed, and results were visualized as de-
scribed in Fig. 1 legend. Whole cell extracts from 3T3-L1 preadipocytes
and adipocytes as well as tissue extracts from the epididymal fat pads
from lean and obese Zucker rats were also examined. This is a repre-
sentative experiment independently performed two times.
FIG. 4. Glycosylation of CNTF receptor complex components
in rat tissues. Tissue extracts were prepared from 8-week-old Spra-
gue-Dawley rats. Eighty g of each extract was incubated with 4 l of
PNGaseF (5,000 units/l) as directed by the manufacturer’s instruction
and then separated by SDS-PAGE, transferred to nitrocellulose, and
subjected to Western blot analysis. Samples were processed, and results
were visualized as described in Fig. 1 legend. This is a representative
experiment independently performed two times.
FIG. 5. Time- and dose-dependent effects of CNTF administra-
tion on the phosphorylation and nuclear translocation of STAT
proteins in 3T3-L1 cells. A, cytosolic and nuclear extracts were pre-
pared from fully differentiated 3T3-L1 adipocytes following a treatment
with 0.8 nM CNTF for the times indicated at the top of the figure. B,
cytosolic and nuclear extracts were prepared from fully differentiated
3T3-L1 adipocytes following a 10-min treatment with CNTF at the
doses indicated. C, whole cell extracts were prepared from both prea-
dipocytes and from fully differentiated 3T3-L1 adipocytes following a
10-min treatment with CNTF at the doses shown in the figure. Seventy-
five g of each extract was separated by SDS-PAGE, transferred to
nitrocellulose, and subjected to Western blot analysis. Samples were
processed, and the results were visualized as described in Fig. 1 legend.
This is a representative experiment independently performed three
times.
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STATs, PPAR, or C/EBP. There were no notable differences
in the levels of gp130 and LIFR expression, and chronic CNTF
treatment was insufficient to induce the expression of
CNTFR. A positive control of confluent preadipocytes is
shown for CNTFR expression. We also observed that CNTF
treatment did not alter the expression of acrp 30 in 3T3-L1
adipocytes. Moreover, CNTF had no effect on the expression or
secretion of leptin from 3T3-L1 adipocytes (data not shown).
Interestingly, CNTF treatment resulted in a decrease of FAS
expression and a substantial increase in the expression of
IRS-1. Also, the levels of the 67-kDa SREBP-1 protein were
slightly decreased by CNTF treatment after 72 h.
Although we did not observe substantial levels of CNTFR in
cultured 3T3-L1 adipocytes (Figs. 2, 3, and 5), we were able to
detect the expression of CNTFR in rodent adipose tissue from
an obese Zucker rat, and the levels of this receptor appeared to
be up-regulated in conditions of obesity (Fig. 3). Hence, we
examined the expression of CNTF receptors in adipose tissue of
additional rodent models of obesity/type II diabetes. Whole cell
extracts were prepared from epididymal fat pads of five ob/ob
and five ob/ lean littermates. As shown in Fig. 8A, we ob-
served very little expression of CNTFR in the adipose tissue of
lean mice, but we observed a substantial increase in the ex-
pression of this receptor in three of the five obese insulin-
resistant ob/ob littermates. In the other two ob/ob mice, there
was a modest increase in CNTFR expression. In addition, we
observed increased LIFR expression in all five ob/ob mice com-
pared with lean littermates, but we did not observe any sub-
stantial changes in gp130 expression. We also examined the
expression of these proteins in the epididymal fat pads of fa/
and fa/fa rats. As shown in Fig. 8B, the expression of CNTFR
was also substantially up-regulated in this rodent model of
obesity/type II diabetes. However, we did not observe an in-
crease in LIFR levels in the fa/fa rats as compared with their
lean littermates, although there was a modest increase in
gp130 levels in adipose tissue from fa/fa rats. We also examined
the expression of these receptors in transgenic mice that over
express agouti under the control of the -actin promoter, a
condition that causes obesity and type II diabetes (29). We
observed a substantial increase in CNTFR levels in the epi-
didymal fat pads of three obese transgenic mice (Tg/) com-
pared with wild-type lean (/) mice. There was also a modest
decrease in LIFR and gp130 in the fat pads of mice with
agouti-induced obesity. Finally, we examined the expression of
CNTF receptors after low fat or high fat feeding in C57B1/6J
mice. Seven mice from each condition were analyzed for CNTF
receptor expression. The results in Fig. 8D only include three
animals per condition. However, this pattern of regulation was
observed for all seven animals examined for each condition
(data not shown). In C57B1/6J mice, we observed an increase in
CNTFR levels with high fat feeding after 12 weeks. A similar
pattern was also observed after 7 weeks (data not shown).
Overall, there was no modulation of LIFR or gp130 with high
fat feeding in the C57Bl/6J mice.
We have shown that cultured adipocytes do not express
CNTFR, but rodent adipose tissues express detectable levels
of the receptor. Therefore, we examined the ability of CNTF to
activate STAT 3 in vivo. C57Bl/6J mice were given an intrap-
eritoneal injection of CNTF (33.3 g/kg) or vehicle (saline)
control. Fifteen minutes after the injection, the mice were
sacrificed, and epididymal adipose tissue, brains, and skeletal
muscle were immediately removed and frozen in liquid nitro-
gen. Whole cell extracts were prepared from these tissues and
FIG. 6. The effects of acute CNTF administration on the ex-
pression of adipocyte proteins. Whole cell extracts were prepared
from fully differentiated 3T3-L1 adipocytes treated with 0.8 nM CNTF
for the times shown. Seventy-five g of each extract was separated by
SDS-PAGE, transferred to nitrocellulose, and subjected to Western blot
analysis. Samples were processed and results were visualized as de-
scribed in Fig. 1 legend. This is a representative experiment independ-
ently performed three times.
FIG. 7. The effects of chronic CNTF administration on the
expression of adipocyte proteins. Whole cell extracts were prepared
from fully differentiated 3T3-L1 adipocytes treated with 0.8 nM CNTF
for the times indicated at the top of the figure. Seventy-five g of each
extract was separated by SDS-PAGE, transferred to nitrocellulose, and
subjected to Western blot analysis. Samples were processed, and results
were visualized as described in Fig. 1 legend. This is a representative
experiment independently performed three times.
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analyzed for STAT 3 phosphorylation by Western blot analysis.
As shown in Fig. 9, acute CNTF treatment resulted in the
activation of STAT 3 in epididymal adipose tissue. We were
unable to detect STAT 3 phosphorylation in the adipose tissue
of five saline-injected mice, but four of the five CNTF injected
mice had readily detectable levels of phosphorylated STAT 3.
The increase in STAT 3 phosphorylation was not due to in-
creased STAT 3 expression. Also, the expression of LIFR was
not changed, and the levels of CNTFR were variable in the 10
mice. The results in Fig. 9B demonstrate constitutive STAT 3
phosphorylation in brain, which was unresponsive to exoge-
nous CNTF. Moreover, we observed an increase in STAT 3
phosphorylation in the skeletal muscle of CNTF-treated ani-
mals, as compared with saline controls. As indicated previously
(Fig. 2), the levels of CNTFR in the brain are substantially
greater than the levels in skeletal muscle.
Our results demonstrate that CNTFR receptor expression
was decreased during the adipogenesis of 3T3-L1 cells but
expressed in the fat pads of rodents. Therefore, we fractionated
epididymal fat pads from C57Bl/6J mice to determine whether
the CNTFR receptor was expressed in the stromovascular
fraction or in the adipocytes. As shown in Fig. 10, our results
clearly demonstrate that CNTFR is expressed highly in the
adipocytes, and STAT 3 is expressed at higher levels in the
stromovascular portion. We hypothesize that the loss of
CNTFR that occurs during differentiation in vitro (Fig. 2)
could be an artifact of cell culture because this receptor is
expressed in native adipocytes (Fig. 10) and in media obtained
from cultured 3T3-L1 adipocytes (data not shown).
FIG. 8. The expression of CNTF receptor components in the adipose tissue of lean and obese rodents. Whole cell extracts were isolated
from the epididymal fat pads of 7-week-old ob/ (lean) and ob/ob (obese) littermate mice (A), 8-week-old fa/ (lean) and fa/fa (obese) littermate rats
(B), 12-week-old lean mice or obese agouti (Tg/) littermates (C), and 17-week-old C57B1/6J mice fed a low or high fat diet for 12 weeks (D). In
each panel, 75 g of each extract was separated by SDS-PAGE, transferred to nitrocellulose, and subjected to Western blot analysis. Samples were
processed and results were visualized as described in Fig. 1 legend.
FIG. 9. In vivo effect of acute CNTF administration in rodents.
Six-week-old C57Bl/6J mice were given an intraperitoneal injection of
CNTF (33.3 g/kg) or vehicle (saline) control. Fifteen minutes after the
injection, the mice were sacrificed, and epididymal fat pads, brains, and
skeletal muscle were immediately removed and frozen in liquid nitro-
gen. Tissue extracts were analyzed from epididymal fat pads (A) and
brain and skeletal muscle (B). In each panel, 75 g of each extract was
separated by SDS-PAGE, transferred to nitrocellulose, and subjected to
Western blot analysis. Samples were processed, and results were visu-
alized as described in Fig. 1 legend. This is a representative experiment
independently performed two times.
FIG. 10. In vivo expression of CNTFR in epididymal fat pads.
Epididymal fat pads were extracted from 6-week-old lean C57Bl/6J
mice and fractionated into adipocyte and stromovascular fractions.
Seventy-five g of each extract was separated by SDS-PAGE, trans-
ferred to nitrocellulose, and subjected to Western blot analysis. Samples
were processed, and results were visualized as described in Fig. 1
legend.
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Because CNTF administration of ob/ob, db/db, and diet-in-
duced obesity mice has been shown to improve insulin sensi-
tivity in vivo, we examined the ability of CNTF to regulate
insulin-sensitive glucose uptake in 3T3-L1 adipocytes. Fully
differentiated 3T3-L1 adipocytes were treated for 24 h with
CNTF. As shown in Fig. 11A, CNTF treatment resulted in a
notable increase (25–50%) in GLUT 4 levels. However, addi-
tional treatments of CNTF did not result in a further increase
in GLUT 4 levels as chronic CNTF treatment did not substan-
tially increase GLUT 4 mRNA or protein levels (data not
shown). Therefore, we examined the ability of CNTF to affect
glucose uptake. Fully differentiated adipocytes were treated for
72 h with CNTF. Every 24 h, cells were treated with a fresh
bolus of CNTF. Acute insulin treatment (50 nM, 7 min) resulted
in a 5-fold increase in insulin-stimulated glucose uptake and
was relatively unaffected by chronic CNTF treatment (Fig.
11B). In addition, CNTF had no effect on basal glucose uptake.
Because CNTF treatment resulted in an increase in IRS-1
expression levels (Fig. 7), we examined the ability of this cyto-
kine to induce IRS-1 activation, as judged by tyrosine phospho-
rylation at residue 896. As shown in Fig. 12, acute insulin
treatment (15 min) results in the activation of IRS-1 and Akt,
whereas acute CNTF treatment does not. However, CNTF pre-
treatment (30 min) prior to insulin stimulation resulted in an
increased IRS-1 activation (20%) and increased Akt phospho-
rylation (25%). The efficacy of the CNTF is demonstrated by
the activation of STAT 3.
DISCUSSION
In the light of recent findings demonstrating that CNTF
administration results in weight loss and correction of many
other obesity/type II diabetes-related symptoms (19, 22, 24, 30),
we hypothesized that the effects of this cytokine may not be
limited to the central nervous system and that CNTF may also
have effects on peripheral tissues such as adipose tissue. Our in
vitro studies using 3T3-L1 preadipocytes and adipocytes have
shown that CNTF indeed has significant, yet different, effects
on these two cell types. In 3T3-L1 adipocytes we observed that
CNTF was a potent activator of the Jak/STAT pathway, in
particular STAT 3, as well as an activator of a MAPK signaling
cascade that resulted in activation of ERKs 1 and 2. In prea-
dipocytes CNTF elicited similar effects but also resulted in the
activation of Akt. Our studies revealed that two of the three
CNTF receptor components, LIFR and CNTFR, were down-
regulated during the adipogenesis of 3T3-L1 cells. Our study
clearly demonstrates that the expression of CNTFR is sub-
stantially decreased during the course of adipocyte differenti-
ation. Other studies (16) have shown that CNTFR is down-
regulated during astrocyte differentiation. A previous
investigation had also indicated a decrease in LIFR during
adipogenesis (31), but this is the first investigation to demon-
strate a decrease in CNTFR during adipogenesis. We hypoth-
esize that decreased expression of CNTF receptors upon differ-
entiation accounts for cultured adipocytes being less sensitive
to CNTF treatment than preadipocytes, as judged by STAT 3 or
Akt activation.
Although LIFR and CNTFR protein levels are reduced in
cultured adipocytes, as compared with preadipocytes, we ob-
served that adipocytes were still responsive to CNTF. It has
been demonstrated previously (15, 16) that CNTF can induce
signaling in the absence of CNTFR, solely by binding to a
gp130:LIFR dimeric receptor. Acute treatment of CNTF did not
alter the expression levels of any STATs or any other adipocyte
transcription factors in 3T3-L1 adipocytes. Hence, we exam-
ined the chronic effects of CNTF on 3T3-L1 adipocytes, and we
observed that this cytokine affected the expression of several
adipocyte-enriched proteins, including SREBP-1, FAS, GLUT4,
and IRS-1. The reduction in the levels of SREBP-1 and FAS is
indicative of decreased biosynthesis of fatty acids that may
account for some portion of weight loss and decreased fat mass
observed in patients treated with CNTF (Axokine). In agree-
ment with previous findings that this CNTF-induced weight
FIG. 11. CNTF does not cause insulin resistance but increases
GLUT 4 expression. A, whole cell extracts were prepared from fully
differentiated 3T3-L1 adipocytes treated with 0.8 nM CNTF for the
times shown. Seventy-five g of each extract was separated by SDS-
PAGE, transferred to nitrocellulose, and subjected to Western blot
analysis. Samples were processed, and results were visualized as de-
scribed in Fig. 1 legend. B, fully differentiated 3T3-L1 adipocytes were
treated with CNTF for 72 h. A fresh bolus of CNTF was added to the
cells every 24 h. Monolayers of adipocytes were used to examine glucose
uptake as indicated under “Experimental Procedures.” This is a repre-
sentative experiment independently performed four times.
FIG. 12. The effects of acute CNTF treatment on IRS-1 and Akt
activation in 3T3-L1 adipocytes. Whole cell extracts were prepared
from fully differentiated 3T3-L1 adipocytes treated with 0.8 nM CNTF
or 50 nM insulin for the times indicated in the figure. Seventy-five g of
each extract was separated by SDS-PAGE, transferred to nitrocellulose,
and subjected to Western blot analysis. Samples were processed, and
results were visualized as described in Fig. 1 legend. This is a repre-
sentative experiment independently performed three times.
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loss was not due to cachexia or inflammation (22, 25), we did
not observe any effect of CNTF on PPAR or C/EBP, two
transcription factors known to be down-regulated by inflamma-
tory cytokines such as tumor necrosis factor- and interferon-
(32–34). Also, unlike the in vitro effects of other cytokines (32,
35–37), CNTF treatment of 3T3-L1 adipocytes did not result in
the onset of insulin resistance (Fig. 10). Moreover, chronic
CNTF treatment of these cells actually resulted in an increase
in both GLUT4 and IRS-1 protein levels. However, we did not
observe any effects of CNTF on basal or insulin-stimulated
glucose uptake. Clearly, additional experiments are required to
determine whether CNTF can act as an insulin sensitizer.
Nonetheless, we have shown that CNTF appears to act syner-
gistically with insulin to increase the level of IRS-1 and Akt
phosphorylation in 3T3-L1 adipocytes.
Our results strongly suggest that CNTF affects adipose tis-
sue and skeletal muscle in vivo because an acute intraperito-
neal injection of CNTF resulted in STAT 3 activation in both
tissues. We also observed that CNTFR is expressed not only in
brain and skeletal muscle but also in adipose tissue, spleen,
heart, testes, lungs, and stomach. The receptor expression lev-
els, as well as the protein size, vary among these tissues, but
our deglycosylation studies clearly demonstrate that they all
express CNTFR. One of the most important findings we ob-
served was that, in vivo, CNTFR expression was significantly
increased in four different rodent models of obesity/type II
diabetes, including both genetic and diet-induced obesity.
Moreover, we have shown that CNTFR is expressed at higher
levels in the adipocytes as compared with the stromovascular
portion of the fat pad (Fig. 10). Although we observed an
increase in the expression of the LIFR in the ob/ob mice, as
compared with lean littermates, the expression of this receptor
was not altered in the fa/fa rats or in C57Bl/6J mice with
diet-induced obesity.
The results of our study suggest that CNTF and CNTFR
may play a role in the regulation of adipocyte metabolism and,
perhaps, the control of adipose tissue mass. Our results have
led us to hypothesize that CNTF can act as an insulin sensi-
tizer in adipocytes. Therefore, the up-regulation of CNTFR in
adipose tissue of obese/type II diabetic rodents could be an
adaptive response attempting to increase insulin sensitivity.
Interestingly, some studies suggest that CNTFR may not only
act as receptor for CNTF but also as a receptor for another
unknown CNTF-like factor. For example, mice lacking CNTF
develop normally and appear to have no visible defects well into
adulthood, when they develop minor loss of motor neurons (10).
Yet mice lacking CNTFR tend to have severe motor neuron
defects and die perinatally because they fail to initiate feeding
behaviors (11). Also the finding that CNTF expression is unde-
tectable in the feeding-relevant brain sites, which express high
levels of CNTFR (30), further supports the notion that
CNTFR may have additional ligands and/or functions.
In summary, we observed that native as wells as cultured
adipocytes are responsive to CNTF treatment. Interestingly,
CNTFR is not highly expressed in cultured adipocytes but is
readily detectable in rodent adipose tissue and furthermore
highly up-regulated in multiple rodent models of obesity/type II
diabetes. This is the first demonstration that this receptor is
expressed in adipose tissue and that it is highly regulated in
obesity/type II diabetes. Current studies are underway to de-
termine the role of CNTFR in adipose tissue function and
examine the ability of CNTF to act as insulin sensitizer in fat
and muscle.
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